Biologics Inc. announced on March 9 that it will the exclusive specialty pharmacy provider for uridine triacetate (Vistogard, Wellstat Therapeutics), which was approved by the FDA in December as the first emergency treatment for overdose or life-threatening toxicities from 5-fluorouracil (5-FU) or capecitabine.
The drug’s approval was based on results from two open-label trials involving 135 adult and pediatric patients with cancer who had either received an overdose of 5-FU or